期刊文献+

大鼠肌肉组织坏死模型磁共振评价方法的建立

Establishing a magnetic resonance imaging method to evaluate rat muscle tissue necrosis model
原文传递
导出
摘要 目的:探讨磁共振影像技术评价大鼠肌肉组织坏死模型的实验方法,并用病理金标准验证磁共振扫描结果。方法:向6只大鼠左后肢注射0.2 ml无水乙醇,制成骨骼肌坏死模型,分别于造模后0、2、4、8、12、14、16 h进行磁共振扫描,分析图像并得出最佳扫描序列及最佳扫描时间。另取20只模型鼠在最佳扫描条件下行磁共振扫描,扫描后处死行病理检查。对病变区伊文氏蓝染色大体病理图像及T2WI fs图像进行形态比较,并对两者面积比进行分析。结果:T2WI fs时病变范围清晰且排除周围脂肪信号的干扰,为最佳监测序列,12 h为最佳扫描时间。坏死骨骼肌面积在磁共振影像和伊文氏蓝染色大体病理影像上无明显差异。磁共振影像上左后肢坏死骨骼肌面积占可视面积的(7.95±0.18)%,伊文氏蓝染色大体病理影像上左后肢坏死骨骼肌面积占可视面积的(7.91±0.15)%。结论:磁共振影像可作为大鼠骨骼肌坏死模型的评价方法。 Objective:To investigate an experimental method of using magnetic resonance imaging (MRI) techniques to evaluate rat muscle tissue necrosis model. Methods:Firstly,0.2 ml anhydrous ethanol was injected into the left hind limbs of 6 rats to make a skeletal muscle necrosis model. MRI scans were performed after 0,2,4,8,12, 14 h and 16 h respectively to analyze imagines and to find optimal scanning sequence and scanning time. Results: MRI scanning resulted from T2WI fs and 12 h showed clear pathological changing area and excluded the signal interference from peripheral fat,which proved T2WI fs is the optimized scanning sequence and 12 h is the optimized scanning time. Another 20 model rats were used for MRI scans with the optimal scanning sequence and time, then executed after MRI scans for pathological examination. There was no apparent size difference between Evans blue dye pathology images and MRI images of rat skeletal muscle necrosis area. The skeletal muscle necrosis area was (7.95 ± 0.18)% of the viewing area of the left hind in MRI images,and was (7.91 ± 0.15)% in/he Evans blue dye pathology images. Conclusion:MRI scans can be used for evaluating skeletal muscle necrosis.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2013年第5期702-706,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省自然科学基金(BK2010594)
关键词 肌肉坏死 磁共振成像 病理检查 muscle necrosis magnetic resonance imaging pathologic examination
  • 相关文献

参考文献15

  • 1Ni Y. Met alloporphyrins and functional analogues as MRIcontrast agents[J]. Curr Med Imaging Kev,2008,4 (2):96-112.
  • 2Fonge H,Vunckx K,Wang H,et al. Noninvasive detectionand quantification of acute myocardial in farction in rab-bits using mono [ ,23I]iodohypericin SPECT [J]. Eur HeartJ,2008,29(2):260-269.
  • 3Wu X,Ni Y. Rat model of reperfused partial liver in farc-tion :characterization with multiparametric magneticreso-nance imaging,microangiography,and histomorphology [J].Acta Radiol, 2009,50(3): 276-287.
  • 4Kim YB,Kalthoff D,Po C,et al. Connectivity of thalamo-cortical pathway in rat brain : Combined diffusion spec-trum imaging and functional MKI at 11.7T [J]. NMRBiomed ,2012,25(7): 9543-9552.
  • 5Li Y,Weber E,Liu F,et al. The optimization of an 8-channel transceiver volume array for small animal MRI at9.4TIJ]. Conf Proc IEEE Eng Med Biol Soc,2011,2011:2833-2836.
  • 6姚楠,张健,黄德健,霍介格,方志军,刁银军,孙自平,王小宁,倪以成.磁共振成像技术评价考布他汀A4磷酸酯对大鼠移植性肝脏肿瘤的治疗作用[J].中国药科大学学报,2010,41(6):558-562. 被引量:7
  • 7Wang H,Chen F,Ni Y,et al. Hypericin as a marker fordetermination of tissue viability after intratumoral ethanolinjection in a murine liver tumor model[J]. Acad Radiol,2008,15(1):107-113.
  • 8Ni Y,Adzamli K,Miao Y,et al. MRI contrast enhance-ment of necrosis by MP-2269 and gadophrin-2 in a rat[J]. Invest Radiol,2001,36(2) :97-103.
  • 9Xu Q,Qaum T,Adamis AP. Sensitive blood-retinal barri-er breakdown quantitation using Evans blue[J]. InvestOphthalmol Vis Sci,2001,42(3) :789-794.
  • 10Harmer PW’McGeachie JM,Davies MJ,et al. Evans bluedye as an in vivo marker of myofibre damage : optimizingparameters for detecting initial myofibre membrancepermeability[J]. J Anat,2002,200 (Ptl):69-79.

二级参考文献10

  • 1Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies [J]. Clin Cancer Res, 2005, 11(2 Pt 1) :416 -420.
  • 2Koh DM, Blackledge M, Collins DJ, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial [ J ]. Eur Radial, 2009,19 ( 11 ) : 2 728-2 738.
  • 3Wang X,Chen Z,Che J,et al. Development of a rapid and sensitive LC-MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study [ J ]. J Chromatogr B, 2009,877 ( 30 ) : 3 813 - 3 821.
  • 4Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivaseular activity in rat and man as demonstrated by dynamic magnetic resonance imaging [ J ]. J Clin Oncol, 2003,21 ( 15 ) : 2 831 - 2 842.
  • 5Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular eudothelial-cadherin signaling [Jl. J Clin Invest,2005,115 (11 ) :2 992 -3 006.
  • 6Mitrus I, Sochanik A, Cichon T, et al. Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors[ J]. Acta Biochim Pol,2009,56 (1) :161 -165.
  • 7Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity[J]. Clin Cancer Res ,2006 ,12 ( 13 ) :4 090 - 4 094.
  • 8Koh DM, Blackledge M, Collins DJ, et al.Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial [ J ]. Eur Radiol, 2009,19 ( 11 ) : 2 728-2 738.
  • 9Zhang YF, Wang JC, Bian DY, et al. Targeted delivery of RGD- modified liposomes encapsulating both combretastatin A4 and doxorubiein for tumor therapy:in vitro and in vivo studies [J]. Eur J Pharm Biopharm ,2010,74 ( 3 ) :467 - 73.
  • 10陈彬,王顺金.大鼠移植性肝癌模型的建立及其磁共振表现[J].江西医学院学报,2008,48(6):39-41. 被引量:4

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部